IDEX BIOMETRICS ASA (IDEX.OL) Stock Fundamental Analysis

Europe • Euronext Oslo • OSL:IDEX • NO0013536078

5.999 NOK
+0.2 (+3.41%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Taking everything into account, IDEX scores 2 out of 10 in our fundamental rating. IDEX was compared to 57 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of IDEX have multiple concerns. IDEX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IDEX has reported negative net income.
  • IDEX had a negative operating cash flow in the past year.
  • IDEX had negative earnings in each of the past 5 years.
  • IDEX had a negative operating cash flow in each of the past 5 years.
IDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFIDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -133.36%, IDEX is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
  • With a Return On Equity value of -413.86%, IDEX is not doing good in the industry: 92.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -133.36%
ROE -413.86%
ROIC N/A
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
IDEX.OL Yearly ROA, ROE, ROICIDEX.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IDEX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDEX.OL Yearly Profit, Operating, Gross MarginsIDEX.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • IDEX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IDEX has more shares outstanding
  • Compared to 5 years ago, IDEX has more shares outstanding
  • The debt/assets ratio for IDEX has been reduced compared to a year ago.
IDEX.OL Yearly Shares OutstandingIDEX.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
IDEX.OL Yearly Total Debt VS Total AssetsIDEX.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • IDEX has an Altman-Z score of -2.52. This is a bad value and indicates that IDEX is not financially healthy and even has some risk of bankruptcy.
  • IDEX has a worse Altman-Z score (-2.52) than 87.72% of its industry peers.
  • IDEX has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
  • IDEX has a Debt to Equity ratio (0.42) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Altman-Z -2.52
ROIC/WACCN/A
WACC8.38%
IDEX.OL Yearly LT Debt VS Equity VS FCFIDEX.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • IDEX has a Current Ratio of 2.07. This indicates that IDEX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of IDEX (2.07) is better than 68.42% of its industry peers.
  • IDEX has a Quick Ratio of 2.07. This is a bad value and indicates that IDEX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IDEX has a Quick ratio of 0.52. This is amonst the worse of the industry: IDEX underperforms 89.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.07
Quick Ratio 0.52
IDEX.OL Yearly Current Assets VS Current LiabilitesIDEX.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 80.92% over the past year.
  • The Revenue for IDEX has decreased by -83.94% in the past year. This is quite bad
  • Measured over the past years, IDEX shows a quite strong growth in Revenue. The Revenue has been growing by 14.73% on average per year.
EPS 1Y (TTM)80.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.49%
Revenue 1Y (TTM)-83.94%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-100%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IDEX.OL Yearly Revenue VS EstimatesIDEX.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
IDEX.OL Yearly EPS VS EstimatesIDEX.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2025 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • IDEX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 11.55, the valuation of IDEX can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, IDEX is valued a bit cheaper than 75.44% of the companies in the same industry.
  • IDEX is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 11.55
IDEX.OL Price Earnings VS Forward Price EarningsIDEX.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDEX.OL Per share dataIDEX.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IDEX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDEX BIOMETRICS ASA

OSL:IDEX (2/6/2026, 7:00:00 PM)

5.999

+0.2 (+3.41%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)11-13
Earnings (Next)02-16
Inst Owners5.25%
Inst Owner ChangeN/A
Ins Owners34.33%
Ins Owner ChangeN/A
Market Cap105.27M
Revenue(TTM)209.00K
Net Income(TTM)-10.93M
Analysts82.86
Price Target1148.1 (19038.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.55
P/S 51.79
P/FCF N/A
P/OCF N/A
P/B 4.1
P/tB 5.05
EV/EBITDA N/A
EPS(TTM)-10.26
EYN/A
EPS(NY)0.52
Fwd EY8.65%
FCF(TTM)-5.61
FCFYN/A
OCF(TTM)-5.61
OCFYN/A
SpS0.12
BVpS1.46
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -133.36%
ROE -413.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.07
Quick Ratio 0.52
Altman-Z -2.52
F-Score2
WACC8.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.49%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-83.94%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-100%
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1659.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.26%
OCF growth 3YN/A
OCF growth 5YN/A

IDEX BIOMETRICS ASA / IDEX.OL FAQ

What is the ChartMill fundamental rating of IDEX BIOMETRICS ASA (IDEX.OL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IDEX.OL.


What is the valuation status for IDEX stock?

ChartMill assigns a valuation rating of 2 / 10 to IDEX BIOMETRICS ASA (IDEX.OL). This can be considered as Overvalued.


Can you provide the profitability details for IDEX BIOMETRICS ASA?

IDEX BIOMETRICS ASA (IDEX.OL) has a profitability rating of 0 / 10.


What is the financial health of IDEX BIOMETRICS ASA (IDEX.OL) stock?

The financial health rating of IDEX BIOMETRICS ASA (IDEX.OL) is 3 / 10.